Top Tech Companies (1,916)
Don't see your company?
Create a company profile
Evoke Pharma develops therapeutics for the treatment of gastrointestinal diseases.
LynxDx offers technologies that enable early cancer detection and improvement of patient care.
A clinical stage biopharmaceutical company.
Sharps Compliance, Inc., based in Houston, Texas, is a leading developer and provider of superior solutions for improving safety
Caprico Biotechnologies, Inc. is a startup located in Norcross, Georgia focusing in antibody production for flow cytometry and immunohistochemistry.
Developing next generation technologies for precision medicine and drug discovery
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company's lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. In addition, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke and progenitor cell and protein combination therapy for Alzheimer’s disease. More information on Stemedica may be found at www.stemedica.com.
Miromatrix Medical is engaged in the development of fully biological human organs and organ-derived biological products.
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
Maravai LifeSciences enables the miracles of science and improves the human condition through its portfolio of market-leading companies and proprietary technologies. Biomedical innovation is dependent on a reliable supply of reagents in the fields of nucleic acid production and biologics safety testing. From inventive startups to many of the world's leading biopharma, vaccine, diagnostics and cell and gene therapy companies, customers turn to Maravai to solve their complex discovery challenges and help them streamline and scale from research through clinical trials. TriLink BioTechnologies is a global leader in RNA synthesis and scale up, including mRNA production, yield-enhancing proprietary CleanCap® mRNA capping technology, and CDMO services ranging from research to GMP grades. Glen Research leads in specialty reagents for DNA and RNA oligonucleotide synthesis for a broad range of applications. Cygnus Technologies developed the market for bioprocess impurity detection, process-related impurity analytics and viral clearance prior to human trials, regulatory approval and commercial release. Maravai holds a number of patents and offers innovative products and services including CleanCap®, CleanAmp®, GMPLink™, Antibody Affinity Extraction™ (AAE™), EndonucleaseGTP®, PROTEIN A MIX-N-GO™, MockV™, Sterling™, Glen Pak™, Glen Gel-Pak™, Poly-Pak™. Maravai's portfolio companies are ISO-9001:2015 certified and have earned hundreds of thousands of citations in peer-reviewed scientific publications. Founded in 2014 and headquartered in San Diego, Maravai LifeSciences is online at www.maravai.com.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
Biotechnology company developing pharmaceutical therapies for nerve regeneration in the central nervous system.
Embody, Inc. is a commercial-stage company pioneering the next generation in collagen-based tendon and ligament healing for the fast-growing sports medicine market. Founded in 2014, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair.
CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza and other viral infectious diseases.
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Jivana Biotechnology is a preclinical-stage biotechnology company
Re-gen Active Lab is an Irving, Texas, based Biotechnology Company established in 2018 with a goal of revolutionizing regenerative medicine through the development of novel stem cell therapy for wound healing, regeneration, anti-inflammatory, and well-being applications. We collaborate with hospitals and universities around the globe to exploit the paramount potential of stem cells through research and development. All our products are developed in our own cutting edge ISO Class 3 laboratory facility by highly trained scientists and engineers. We have total control over all the steps involved in our product development process to achieve high levels of safety, purity, potency, viability, and reproducibility (batch to batch consistency).
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com.
Synchron is a leading implantable brain computer interface company. The stentrode is the first commercial implantable brain computer interface to receive an FDA IDE for in human clinical trials.
At Bionano Genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. Our team is not afraid to venture into uncharted territory to look for answers. We welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. Our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. Saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. At Bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality of life for all.
